Micro‐RNA‐155 inhibits IFN‐γ signaling in CD4<sup>+</sup> T cells

Arnob Banerjee(Johnson & Johnson (United States)), Steven L. Reiner(Columbia University Irving Medical Center), Felix Schambach(The Wistar Institute), Caitlin S. DeJong(The Wistar Institute), Scott M. Hammond(University of North Carolina at Chapel Hill)

European Journal of Immunology

October 29, 2009

10.1002/eji.200939381

Cited by 251

Related Papers

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

|The Lancet|2021|1.7k

Teclistamab in Relapsed or Refractory Multiple Myeloma

|New England Journal of Medicine|2022|1.2k

Asymmetric T Lymphocyte Division in the Initiation of Adaptive Immune Responses

|Science|2007|852

Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing

|RNA|2008|678

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

|Journal of Clinical Oncology|2022|647